Skip to main content
. 2020 Nov 30;10:553837. doi: 10.3389/fcimb.2020.553837

Figure 1.

Figure 1

SARS-CoV-2 N-protein specific antibody selection and cross reaction (A). SARS-CoV-2 N-protein was chose for antigen immunoassay (B). The sequence comparison between SARS-CoV-2 N-protein and that of the other 6 kinds of coronaviruses. From the top to the bottom of the list: 1, HCoV-229E (AOG74787.1_N); 2, SARS-CoV-2 (YP009724397.2_N); 3, HCoV-HKU1(AGW27885.1_N); 4,MERS-CoV (AHC74105.1_N); 5, HCoV-NL63 (AFV53152.1_N); 6, HCoV-OC43 (QDH43730.1_N); 7, SARS-CoV ShanghaiQXC1(AAR86795.1_N); 8,consensus sequence, the black area (C). The expression of SARS-CoV-2 N-protein (D). Affinity determination between monoclonal antibody and SARS-CoV-2 N-protein. 6A8, 6A6, 7e4, 1c7, 14b9, 7a7, and 1B12 represent seven monoclonal antibodies selected from antibody library of Beijing Biosynthesis Biotechnology Co. Ltd (E). Cross-reaction result. Anti-SARS-CoV-2 N-protein monoclonal antibody-1 and antibody-2 were selected as immune target.